CN109069483A - 西博帕多的滴定 - Google Patents

西博帕多的滴定 Download PDF

Info

Publication number
CN109069483A
CN109069483A CN201780013921.3A CN201780013921A CN109069483A CN 109069483 A CN109069483 A CN 109069483A CN 201780013921 A CN201780013921 A CN 201780013921A CN 109069483 A CN109069483 A CN 109069483A
Authority
CN
China
Prior art keywords
bopaduo
days
daily dose
administration interval
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780013921.3A
Other languages
English (en)
Chinese (zh)
Inventor
王少楠
C.皮亚纳
R.布尔西
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Parker Therapeutics
Original Assignee
Gruenenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal GmbH filed Critical Gruenenthal GmbH
Priority to CN202410387184.5A priority Critical patent/CN118286209A/zh
Publication of CN109069483A publication Critical patent/CN109069483A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201780013921.3A 2016-02-29 2017-02-28 西博帕多的滴定 Pending CN109069483A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410387184.5A CN118286209A (zh) 2016-02-29 2017-02-28 西博帕多的滴定

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP16157868.7 2016-02-29
EP16157868 2016-02-29
EP16020302 2016-08-11
EP16020302.2 2016-08-11
PCT/EP2017/025034 WO2017148595A1 (en) 2016-02-29 2017-02-28 Titration of cebranopadol

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410387184.5A Division CN118286209A (zh) 2016-02-29 2017-02-28 西博帕多的滴定

Publications (1)

Publication Number Publication Date
CN109069483A true CN109069483A (zh) 2018-12-21

Family

ID=58185482

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780013921.3A Pending CN109069483A (zh) 2016-02-29 2017-02-28 西博帕多的滴定
CN202410387184.5A Pending CN118286209A (zh) 2016-02-29 2017-02-28 西博帕多的滴定

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410387184.5A Pending CN118286209A (zh) 2016-02-29 2017-02-28 西博帕多的滴定

Country Status (10)

Country Link
US (3) US11229625B2 (https=)
EP (1) EP3423054A1 (https=)
JP (2) JP7373904B2 (https=)
CN (2) CN109069483A (https=)
AU (1) AU2017226830B2 (https=)
BR (1) BR112018017167A2 (https=)
CA (1) CA3015420C (https=)
IL (1) IL261133A (https=)
MX (1) MX2018010367A (https=)
WO (1) WO2017148595A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7373904B2 (ja) 2016-02-29 2023-11-06 パーク・セラピューティクス・インコーポレイテッド セブラノパドールの滴定

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6339105B1 (en) * 1999-10-12 2002-01-15 Ortho-Mcneil Pharmaceutical, Inc. Analgesic regimen
CN1346266A (zh) * 1998-11-02 2002-04-24 奥索-麦克尼尔药品公司 止痛治疗方案
CN103237545A (zh) * 2010-08-04 2013-08-07 格吕伦塔尔有限公司 治疗神经性疼痛的含6’-氟-(N-甲基-或N,N-二甲基-)-4-苯基-4’,9’-二氢-3’H-螺[环己烷-1,1’-吡喃并[3,4,b]吲哚]-4-胺的药物剂型

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10252667A1 (de) 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DK1572167T3 (da) 2002-12-13 2008-10-13 Euro Celtique Sa Transdermal buprenophindoseringsbehandlingsplan for analgesi
US7413749B2 (en) 2003-03-11 2008-08-19 Purdue Pharma L.P. Titration dosing regimen for controlled release tramadol
DE102006046745A1 (de) 2006-09-29 2008-04-03 Grünenthal GmbH Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz
EP1985292A1 (en) 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol
WO2012016699A2 (en) 2010-08-04 2012-02-09 Grünenthal GmbH Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4,9'-dihydro-3'h-spiro[cylohexane-1,1'-pyrano[3,4,b]indol]-4-amine
WO2012016703A2 (en) 2010-08-04 2012-02-09 Grünenthal GmbH Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine
AU2011287952B2 (en) 2010-08-04 2014-08-21 Grünenthal GmbH Pharmaceutical dosage form comprising 6'-fluoro-(N-methyl- or N,N-dimethyl-)-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane- 1,1'-pyrano[3,4,b]indol]-4-amine
EP2649044B1 (en) 2010-12-08 2017-09-20 Grünenthal GmbH Method for synthesising substituted aminocyclohexanone derivatives
US8614245B2 (en) 2011-07-08 2013-12-24 Gruenenthal Gmbh Crystalline (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine
CN103649094B (zh) 2011-07-08 2017-05-24 格吕伦塔尔有限公司 晶态的(1r,4r)‑6’‑氟‑N,N‑二甲基‑4‑苯基‑4’,9’‑二氢‑3’H‑螺[环己烷‑1,1’‑吡喃并[3,4,b]吲哚]‑4‑胺
ES2605786T3 (es) 2011-12-12 2017-03-16 Grünenthal GmbH Formas sólidas de clorhidrato de (1R,4R)-6'-fluor-N,N-dimetil-4-fenil-4',9'-dihidro-3'H-espiro[ciclohexano-1,1'-pirano[3,4b]indol]-4-amina
RS54960B1 (sr) 2011-12-12 2016-11-30 Gruenenthal Gmbh Čvrsti oblici (1r,4r)-6'-fluoro-(n,n-dimetil)-4-fenil-4',9'-dihidro-3'h-spiro-[cikloheksan-1,1'-pirano-[3,4,b]indol]-4-amina i sumporne kiseline
CN104159902B (zh) 2011-12-12 2016-05-04 格吕伦塔尔有限公司 制备(1r,4r)-6’-氟-(N,N-二甲基-和N-甲基)-4-苯基-4’,9’-二氢-3’H-螺[环己烷-1,1’-吡喃并[3,4,b]吲哚]-4-胺的方法
US20130310435A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol
US9308196B2 (en) 2012-05-18 2016-04-12 Gruenenthal Gmbh Pharmaceutical composition comprising (1 r,4r) -6'-fluoro-N ,N-dimethyl-4-phenyl-4',9'-d ihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam
US8912226B2 (en) 2012-05-18 2014-12-16 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r) -6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a NSAR
US9320725B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid
US9320729B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative
EP3110797B1 (en) 2014-02-27 2018-08-29 Grünenthal GmbH Process for the preparation of 5-fluorotryptophol
JP6673924B2 (ja) 2015-01-23 2020-03-25 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 肝機能障害および／または腎機能障害を有する対象における疼痛を治療するためのセブラノパドール
JP7373904B2 (ja) 2016-02-29 2023-11-06 パーク・セラピューティクス・インコーポレイテッド セブラノパドールの滴定

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1346266A (zh) * 1998-11-02 2002-04-24 奥索-麦克尼尔药品公司 止痛治疗方案
US6339105B1 (en) * 1999-10-12 2002-01-15 Ortho-Mcneil Pharmaceutical, Inc. Analgesic regimen
CN103237545A (zh) * 2010-08-04 2013-08-07 格吕伦塔尔有限公司 治疗神经性疼痛的含6’-氟-(N-甲基-或N,N-二甲基-)-4-苯基-4’,9’-二氢-3’H-螺[环己烷-1,1’-吡喃并[3,4,b]吲哚]-4-胺的药物剂型

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FLAMINIA COLUZZI: ""Good clinical practice guide for opioids in pain management: the three Ts-titration(trial),tweaking(tailoring),transition(tapering)"", 《REV BRAS ANESTESIOL》 *
KINGA SALAT: ""Cebranopadol: a first-in-class potent analgesic agent with agonistic activity at nociceptin/orphanin FQ and opioid receptors"", 《EXPERT OPINION ON INVESTIGATIONAL DRUGS》 *

Also Published As

Publication number Publication date
JP2019507148A (ja) 2019-03-14
JP2021169472A (ja) 2021-10-28
IL261133A (en) 2018-10-31
CN118286209A (zh) 2024-07-05
EP3423054A1 (en) 2019-01-09
US20180369199A1 (en) 2018-12-27
CA3015420A1 (en) 2017-09-08
CA3015420C (en) 2023-09-26
US20250255849A1 (en) 2025-08-14
US11229625B2 (en) 2022-01-25
BR112018017167A2 (pt) 2019-01-02
MX2018010367A (es) 2018-12-10
AU2017226830A1 (en) 2018-08-16
JP7373904B2 (ja) 2023-11-06
US12161627B2 (en) 2024-12-10
US20220110914A1 (en) 2022-04-14
AU2017226830B2 (en) 2021-06-24
WO2017148595A1 (en) 2017-09-08

Similar Documents

Publication Publication Date Title
Zanardi et al. A double-blind, randomised, controlled clinical trial of acetyl-L-carnitine vs. amisulpride in the treatment of dysthymia
EP1742624B1 (en) Dopamine-agonist combination therapy with sedatives for improving sleep quality
Zernikow et al. Pediatric palliative care: use of opioids for the management of pain
US20060122127A1 (en) Methods for reducing the side effects associated with mirtzapine treatment
US20180008593A1 (en) Dosage form containing oxycodone and naloxone
Lauterbach An extension of hypotheses regarding rapid-acting, treatment-refractory, and conventional antidepressant activity of dextromethorphan and dextrorphan
US20230233537A1 (en) Compositions and Kits of Parts Comprising N,N-Dimethyltryptamine and Harmine and Their Use in Therapy
US7892575B2 (en) Orodispersible pharmaceutical composition for oromucosal or sublingual administration of agomelatine
US20220023316A1 (en) Methods for the treatment of depression
KR20220097394A (ko) Gaba-a 수용체 양성 알로스테릭 조절제와 nmda 길항제, nmda 음성 알로스테릭 조절제, 또는 nmda 부분 작용제의 조합
JP2020533415A (ja) ナルコレプシーの処置におけるガボキサドールの使用
CN109069483A (zh) 西博帕多的滴定
EP4583858A1 (en) Combinations comprising psychedelics for the treatment of schizophrenia and other neuropsychiatric and neurologic disorders
Malviya et al. Understanding fentanyl a synthetic piperidine opioid drug: Deciphering the pain-relieving double-edged sword
Grabowski et al. Pharmacotherapy of depression in patients with advanced diseases
CA3084623C (en) The use of 3-(2-(4-(2-methoxyphenyl)piperazin-1-yl)ethyl)quinazolin-4(3h)- one in the treatment of post-traumatic stress disorder
Malviya et al. Deciphering the Pain-Relieving Double-Edged Sword
CN1671368A (zh) 疼痛继发性抑郁（dsp）的治疗
JPWO2014192698A1 (ja) 疼痛治療薬
US20090215796A1 (en) Compositions, Kits and Methods for a Titration Schedule for Pardoprunox Compounds
Poewe et al. Managing the non‐motor symptoms of Parkinson's disease
Levin Fentanyl oral and buccal delivery systems
Scahill Adrenergic Agents in Child and Adolescent Psychiatry

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20221012

Address after: new jersey

Applicant after: Parker Therapeutics

Address before: Ah Xing, Germany

Applicant before: GRuNENTHAL GmbH

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20181221